Kalofonos Isabel 4
4 · Crinetics Pharmaceuticals, Inc. · Filed Jan 13, 2025
Insider Transaction Report
Form 4
Kalofonos Isabel
Chief Commercial Officer
Transactions
- Award
Stock Option (Right to Buy)
2025-01-10+100,000→ 100,000 totalExercise: $40.59Exp: 2035-01-09→ Common Stock (100,000 underlying)
Footnotes (1)
- [F1]The option is exercisable as follows: 25% of the shares subject to the option vest on December 16, 2025, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.